Novavax CEO Says Drugmaker’s Shot Could Be an ‘Ideal’ Booster

Nov. 1, 2021, 4:19 PM

Novavax Inc.’s top executive said the company’s Covid-19 vaccine could be a good booster option for people who have received other shots, as the drugmaker looks to ramp up output and gain approvals around the world.

“Our vaccine is ideal for boosting,” Chief Executive Officer Stanley Erck said in an interview on Monday with Bloomberg Television.

Erck said the Gaithersburg, Maryland-based company has solved manufacturing problems that delayed its vaccine this year and expects to be able to produce 150 million doses a month with partner Serum Institute of India by December.

Novavax was among the companies that received ...

To read the full article log in.

Learn more about a Bloomberg Law subscription.